| Phase 13 trials |
|
Phase 1
|
NCT07005713 |
Jul 2025 → Apr 2026 |
chronic idiopathic urticaria |
BeiGene |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06906809 |
Apr → Oct 2025 |
— |
BeiGene |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06776679 |
Jan → Mar 2025 |
— |
BeiGene |
Completed
|
No outcome recorded
|
| Phase 1/23 trials |
|
Phase 1/2
|
NCT06634589 |
Nov 2024 → Dec 2028 expected |
B-cell neoplasm |
BeOne Medicines |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT05294731 |
May 2022 → Jan 2029 expected |
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma, Richter transformation, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma +3 |
BeiGene |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT05006716 |
Sep 2021 → Nov 2026 expected |
Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma +2 |
BeOne Medicines |
Recruiting
|
No outcome recorded
|
| Phase 21 trial |
|
Phase 2
|
NCT07508995 |
Sep 2026 → Jul 2031 expected |
B-cell chronic lymphocytic leukemia |
M.D. Anderson Cancer Center |
Not yet recruiting
|
No outcome recorded
|
| Phase 33 trials |
|
Phase 3
|
NCT06973187 |
Sep 2025 → Apr 2028 expected |
chronic lymphocytic leukemia/small lymphocytic lymphoma |
BeOne Medicines |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT06970743 |
May 2025 → Nov 2029 expected |
chronic lymphocytic leukemia/small lymphocytic lymphoma |
BeOne Medicines |
Active not recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT06846671 |
Apr 2025 → May 2028 expected |
chronic lymphocytic leukemia/small lymphocytic lymphoma |
BeOne Medicines |
Recruiting
|
No outcome recorded
|